Chemical.AI Shapes the future of chemistry.
Leverage Artificial Intelligence and Big Data to transform research and development.
Drive the innovation in the chemical and pharmaceutical industries.
Leverage Artificial Intelligence and Big Data to transform research and development.
Drive the innovation in the chemical and pharmaceutical industries.
We invented the algorithm independently with data-driven approach after 8+ years’ R&D, combination of chemistry expertise and AI technology. The solution is developed by chemists and for chemists.
The system follows the workflow of routes planning as part of the research process. It enables to design synthetic routes in seconds to minutes, with high feasibility and diversity.
Facilitate valuable data (e.g. ELNs) integration and reaction prediction with custom algorithms. Synthetic accessibility evaluation and forward synthesis are in fast development.
Plan the routes with fast cost analysis or estimation seamlessly. It enables the price quotation and team sharing with automatically generated template-based reports.
Focusing on AI-assisted chemical synthesis route design, it only takes a few seconds to a few minutes to find the synthesis route and recommend the most appropriate synthesis scheme for researchers.
With the help of retrosynthesis algorithm and AIoT automation technology, we can achieve efficient synthesis of compound molecules and assist in the development of new drugs and new materials. Meanwhile, we provide continuous feedback on the effectiveness...
We utilize technologies such as big data, cloud computing, and the IoT to digitally and intelligently transform the chemical synthesis, and gradually towards automatic chemical synthesis. The whole lab operates in a sustainable closed...
The realization of retro-synthesis algorithm landing, enabling organic synthesis laboratory high speed and high throughput generation of molecules.
Predict diverse routes for unreported/reported target molecules within minutes, considering stereochemistry
Make use of your experience and customize the routes by changing conditions or bond-broken positions
Refer to relevant literature for predicted reactions which considers similarity of reaction sites and types
Quickly start search on browser without installation. Easy to set parameters and check route details
Integrate your ELN data in local server to make the most of it while data security is promised
Export the routes as CDX or PDF or picture, share and discuss with your colleagues
According to users’ feedback, for most of target compounds, it only takes a few seconds to 5 minutes to find routes using Quick Search. For complex molecules, enhanced prediction capability will provide diverse routes using Advanced Search (up to 30 min). Functions for interactive route design can make use of your own experience to improve the predicted route. Furthermore, BBs/ELN integration can leverage both the AI tool and your internal data to improve the prediction results.
renewal clients
top pharmas/CROs
local deployed customers
online/local users
There are two versions: Free Version and Pro Version (recommended to use). After registering in this website, you can use the Free Version easily. For the Pro Version, please get in touch.
There are 3 basic differences between the two versions. a, Cutting-edge and update-to-date Algorithm for Pro Version with additional functions, such as chirality, reaction center and regioselectivity, etc. b, Reaction Data: Free version > 4M; Pro Version continues the update. c, Update: Free version updated to end of 2017, Pro version continues to update frequently.
Most target compounds (known or novel) can be completed in seconds to 5 minutes, while more diversity or high complex molecules will around 30 minutes.
XuanZhu BioPharm and Chemical.AI announce collaboration focusing on cancer, metabolism, digestion and other fields, jointly to develop new drugs with proprietary intellectual property rights. Back in 2019, Chemical.AI has closed Angel Round with FreeS Fund...
As everyone knows, it will take 10 to 15 years and costs at least 1 billion dollars for an experimental drug after initial discovery to gain FDA approval, and needs to go through a series of research processes including vitro toxicity test, pre-clinical animal experiments...
Chemical.AI, a global leader in Artificial Intelligence (AI) for synthesis route design and prediction and Chemaxon, a leading chemical and biological software development company, today announced a strategic partnership to create the possibility for end users...
On April 19th, 2022, Chemical.AI, a high-tech company empowering chemistry with AI and ML, announced a strategic partnership with Scilligence, a web-based informatics solution provider for R&D. The two parties will co-develop high-efficiency data integration...
Nowadays, artificial intelligence is widely used in new drug discovery, such as target screening, molecular design, and activity prediction etc. As far back as 50 years ago, Nobel Laureate E.J. Corey had tried to use computer technology to assist retrosynthesis route design...
DeepVerse, together with Bota Bio, Chemical.AI, Foreseen and Nest.Bio, hereby organizes the first nationwide AI4Science Hackathon for researchers and students, providing a cross-disciplinary platform to foster innovations, where you can present...
Chemical.AI's Synthetic Accessibility Module based on fast synthesis planning was involved in the de novo design platform (SECSE) to find novel, diverse and accessible small molecules as a starting point in drug discovery for further validation...
Chemical.AI recently announced the closing of nearly $15 million Series A+ funding led by Source Code Capital, with participation from Sequoia China, FreesFund and Hofon Capital, to support the construction and improvement of automated synthesis platform...
In June 2021, Chemical.AI, an R&D technology company empowering chemistry with AI, announced a strategic partnership with Livzon Pharma and Joincare Pharma which are dedicated to discovering and supporting the development of leading...
Chemical.AI recently announced the completion of a Series A funding of more than 5 Million USD, led by Sequoia China Seed Fund, and with participation from Nest.Bio Ventures and existing shareholder FreesFund, to support marketing penetration...
Partnership will accelerate development of AI tools and enhance industry-available services such as next generation Computer Aided Synthesis Planning (CASP)
Strasbourg,
France, and Wuhan, China, January 25, 2021 – NovAliX...
